Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Harvard Business School
Dow
McKinsey
Express Scripts

Last Updated: October 13, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,034,311

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,034,311
Title:Pyridin-2(1 H)-one derivatives as JAK inhibitors
Abstract: New pyridin-2(1H)-one derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK). ##STR00001##
Inventor(s): Eastwood; Paul Robert (Barcelona, ES), Bach Tana; Jordi (Barcelona, ES), Pages Santacana; Lluis Miquel (Barcelona, ES)
Assignee: ALMIRALL, S.A. (Barcelona, ES)
Application Number:14/236,340
Patent Claims:1. A compound of formula (I): ##STR00007## or a pharmaceutically acceptable salt, solvate, N-oxide, stereoisomer, or deuterated derivative thereof, wherein, m is 0, 1, 2 or 3; X and Y are independently chosen from a nitrogen atom or a --CR.sub.6 group, wherein at least one of X and Y is a --CR.sub.6 group; A and B are independently chosen from a nitrogen atom or a --CR.sub.7 group, wherein at least one of A and B is a --CR.sub.7 group; D is chosen from a nitrogen atom or a --CR.sub.5 group, wherein, when one of A and B is a nitrogen atom, D is a --CR.sub.5 group; W is chosen from a --NR.sub.8-- group, a --(CR.sub.9R.sub.10)-- group, --O-- or --S--; R.sub.1 is chosen from a hydrogen atom, a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.1-C.sub.4 alkoxy group, a C.sub.3-C.sub.10 cycloalkyl group, a C.sub.3-C.sub.10 cycloalkenyl group, a monocyclic or bicyclic C.sub.6-C.sub.14 aryl group, a 5- to 14-membered heteroaryl group containing at least one heteroatom chosen from O, S or N, or a 5- to 14-membered heterocyclyl group containing at least one heteroatom chosen from O, S or N, wherein the cycloalkyl, cycloalkenyl, aryl, heteroaryl, and heterocyclyl groups are unsubstituted or substituted by at least one substituent chosen from a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.1-C.sub.4 alkylsulfonyl group, a C.sub.3-C.sub.7 cycloalkyl group, a phenyl group, a pyridyl group, a pyrimidinyl group or a piperidyl group; R.sub.2 and R.sub.7 are independently chosen from a hydrogen atom, a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.10 cycloalkyl group, a C.sub.3-C.sub.10 cycloalkenyl group, a monocyclic or bicyclic C.sub.6-C.sub.14 aryl group, a 5- to 14-membered heteroaryl group containing at least one heteroatom chosen from O, S or N, a 5- to 14-membered heterocyclyl group containing at least one heteroatom chosen from O, S or N, or a bicyclyl group which is a monocyclic C.sub.6-C.sub.9 aryl or 5- to 9-membered heteroaryl group fused to a 5- to 9-membered cycloalkyl or heterocyclyl group, wherein the heteroaryl the heterocyclyl groups contain at least one heteroatom chosen from O, S or N, wherein the cycloalkyl, cycloalkenyl, aryl, heteroaryl, and heterocyclyl groups, and the bicyclyl group which is a monocyclic C.sub.6-C.sub.9 aryl or 5- to 9-membered heteroaryl group fused to a 5- to 9-membered cycloalkyl or heterocyclyl group are unsubstituted or substituted by at least one substituent chosen from a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a monocyclic or bicyclic C.sub.6-C.sub.14 aryl group, a 5- to 14-membered heteroaryl group containing at least one heteroatom chosen from O, S or N, a 5- to 14-membered heterocyclyl group containing at least one heteroatom chosen from O, S or N, a --(CH.sub.2).sub.1-3CN group, a --(CH.sub.2).sub.nOR.sub.11 group, a --NR.sub.11R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--NR.sub.12R.sub.13 group, a --C(O)--(CH.sub.2).sub.1-3--CN group, a --C(O)--(CH.sub.2).sub.n--R.sub.11 group, a --(CH.sub.2).sub.n'--C(O)--(CH.sub.2).sub.n--NR.sub.11R.sub.12 group, a --(CH.sub.2).sub.n'--S(O).sub.2(CH.sub.2).sub.nR.sub.11 group, a --(CH.sub.2).sub.n'--S(O).sub.2(CH.sub.2).sub.nNR.sub.11R.sub.12 group, a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nR.sub.12 group or a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nNR.sub.12R.sub.13 group, wherein n' and n are independently 0, 1 or 2, and further wherein the monocyclic or bicyclic C.sub.6-C.sub.14 aryl group is unsubstituted or further substituted by at least one carboxyl group; R.sub.3 and R.sub.4 are independently chosen from a hydrogen atom, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group or a linear or branched C.sub.1-C.sub.6 alkyl group, wherein the alkyl group is unsubstituted or substituted by at least one substituent chosen from a C.sub.1-C.sub.4 alkoxy group, a cyano group, a C.sub.3-C.sub.7 cycloalkyl group, a phenyl group, a pyridyl group, a pyrimidinyl group or a piperidyl group; R.sub.5 and R.sub.6 are independently chosen from a hydrogen atom, a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.10 cycloalkyl group, a C.sub.3-C.sub.10 cycloalkenyl group, a monocyclic or bicyclic C.sub.6-C.sub.14 aryl group, a 5- to 14-membered heteroaryl group containing at least one heteroatom chosen from O, S or N, a 5- to 14-membered heterocyclyl group containing at least one heteroatom chosen from O, S or N, a --(CH.sub.2).sub.nOR.sub.11 group, a --NR.sub.11R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--NR.sub.12R.sub.13 group, a --C(O)--(CH.sub.2).sub.1-3--CN group, a --C(O)--(CH.sub.2).sub.n--R.sub.11 group, a --C(O)--(CH.sub.2).sub.n--NR.sub.11 R.sub.12 group, a --S(O).sub.2(CH.sub.2).sub.nR.sub.11 group, a --S(O).sub.2(CH.sub.2).sub.nNR.sub.11R.sub.12 group, a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nR.sub.12 group or a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nNR.sub.12R.sub.13 group, wherein each n is 0, 1 or 2, and further wherein the cycloalkyl, cycloalkenyl, aryl, heteroaryl, and heterocyclyl groups are unsubstituted or substituted by at least one substituent chosen from a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl, a phenyl group, a pyridyl group, a pyrimidinyl group, a piperidyl group or a --C(O)--(CH.sub.2).sub.n--NR.sub.11R.sub.12 group, wherein n is 0, 1 or 2; R.sub.8, R.sub.9 and R.sub.10 are independently chosen from a hydrogen atom, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, or a linear or branched C.sub.1-C.sub.6 alkyl group, wherein the alkyl group is unsubstituted or substituted by at least one substituent chosen from a C.sub.1-C.sub.4 alkoxy group, a cyano group, a C.sub.3-C.sub.7 cycloalkyl group, a phenyl group, a pyridyl group, a pyrimidinyl group, or a piperidyl group; and R.sub.11, R.sub.12 and R.sub.13 are independently chosen from a hydrogen atom, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a 5- to 9-membered heterocyclyl group contaning one, two or three heteroatoms chosen from O, S or N, wherein the heterocyclyl group is unsubstituted or substituted by at least one substituent chosen from a halogen atom, a hydroxyl group, a linear or branched C.sub.1-C.sub.4 alkyl group, a C.sub.1-C.sub.4 haloalkyl group or a C.sub.1-C.sub.4 hydroxyalkyl group, or linear or branched C.sub.1-C.sub.6 alkyl group, wherein the alkyl group is unsubstituted or substituted by at least one substituent chosen from a C.sub.1-C.sub.4 alkoxy group, a cyano group, a C.sub.3-C.sub.7 cycloalkyl group, a phenyl group, a pyridyl group, a pyrimidinyl group or a piperidyl group, with the proviso that the compound of formula (I) is not: a) 3-[[5-Chloro-2-[[2,5-dimethyl-4-(piperidin-4-yl)phenyl]amino]pyri- midin-4-yl]amino]pyridin-2(1H)-one; and b) 2-[7-[[5-Chloro-4-[(2-oxo-1,2-dihydropyridin-3-yl)amino]pyrimidin-2-yl]am- ino]-8-methoxy-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl]-N,N-dimethylacetamid- e.

2. The compound according to claim 1, wherein when D represents a nitrogen atom, A and B are each independently a --CR.sub.7 group and m is 0, then R.sub.2 is not a substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepine group or a phenyl group substituted by a piperidinyl group.

3. The compound according to claim 1 of formula (I'): ##STR00008## wherein, m is 0, 1, 2, or 3; X and Y are independently chosen from a nitrogen atom or a --CR.sub.6 group, wherein at least one of X and Y is a --CR.sub.6 group; A and B are independently chosen from a nitrogen atom or a --CR.sub.7 group, wherein at least one of A and B is a --CR.sub.7 group; W is chosen from a --NR.sub.8-- group, a --(CR.sub.9R.sub.10)-- group, --O-- or --S--; R.sub.1 is chosen from a hydrogen atom, a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.1-C.sub.4 alkoxy group, a C.sub.3-C.sub.10 cycloalkyl group, a C.sub.3-C.sub.10 cycloalkenyl group, a monocyclic or bicyclic C.sub.6-C.sub.14 aryl group, a 5- to 14-membered heteroaryl group containing at least one heteroatom chosen from O, S or N, or a 5- to 14-membered heterocyclyl group containing at least one heteroatom chosen from O, S or N, wherein the cycloalkyl, cycloalkenyl, aryl, heteroaryl, and heterocyclyl groups are unsubstituted or substituted by at least one substituent chosen from a halogen atom, a cyano group, a linear or branched C1-C.sub.6 alkyl group, a C.sub.1-C4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.1-C.sub.4 alkylsulfonyl group, a C.sub.3-C.sub.7 cycloalkyl group, a phenyl group, a pyridyl group, a pyrimidinyl group or a piperidyl group; R.sub.2 and R.sub.7 are independently chosen from a hydrogen atom, a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.10 cycloalkyl group, a C.sub.3-C.sub.10 cycloalkenyl group, a monocyclic or bicyclic C.sub.6-C.sub.14 aryl group, a 5- to 14-membered heteroaryl group containing at least one heteroatom chosen from O, S or N, a 5- to 14-membered heterocyclyl group containing at least one heteroatom chosen from O, S or N, or a bicyclyl group which is a monocyclic C.sub.6-C.sub.9 aryl or 5- to 9-membered heteroaryl group fused to a 5- to 9-membered cycloalkyl or heterocyclyl group, wherein the heteroaryl and the heterocyclyl groups contain at least one heteroatom chosen from O, S or N, wherein the cycloalkyl, cycloalkenyl, aryl, heteroaryl, and heterocyclyl groups, and the bicyclyl group which is a monocyclic C.sub.6-C.sub.9 aryl or 5- to 9-membered heteroaryl group fused to a 5- to 9-membered cycloalkyl or heterocyclyl group are unsubstituted or substituted by at least one substituent chosen from a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a monocyclic or bicyclic C.sub.6-C.sub.14 aryl group, a 5- to 14-membered heteroaryl group containing at least one heteroatom chosen from O, S or N, a 5- to 14-membered heterocyclyl group containing at least one heteroatom chosen from O, S or N, a --(CH.sub.2).sub.1-3CN group, a --(CH.sub.2).sub.nOR.sub.11 group, a --NR.sub.11R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--NR.sub.12R.sub.13 group, a --C(O)--(CH.sub.2).sub.1-3--CN group, a --C(O)--(CH.sub.2).sub.n--R.sub.11 group, a --C(O)--(CH.sub.2).sub.n--NR.sub.11R.sub.12 group, a --S(O).sub.2(CH.sub.2).sub.nR.sub.11 group, a --S(O).sub.2(CH.sub.2).sub.nNR.sub.11 R.sub.12 group, a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nR.sub.12 group or a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nNR.sub.12R.sub.13 group, wherein each n is 0, 1 or 2, and further wherein the monocyclic or bicyclic C.sub.6-C.sub.14 aryl group is unsubstituted or further substituted by at least one carboxyl group; R.sub.3 and R.sub.4 are independently chosen from a hydrogen atom, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, or a linear or branched C.sub.1-C.sub.6 alkyl group, wherein the alkyl group is unsubstituted or substituted by at least one substituent chosen from a C.sub.1-C.sub.4 alkoxy group, a cyano group, a C.sub.3-C.sub.7 cycloalkyl group, a phenyl group, a pyridyl group, a pyrimidinyl group or a piperidyl group; R.sub.5 and R.sub.6 are each independently chosen from a hydrogen atom, a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.10 cycloalkyl group, a C.sub.3-C10 cycloalkenyl group, a monocyclic or bicyclic C.sub.6-C.sub.14 aryl group, a 5- to 14-membered heteroaryl group containing at least one heteroatom chosen from O, S or N, a 5- to 14-membered heterocyclyl group containing at least one heteroatom chosen from O, S or N, a --(CH.sub.2).sub.nOR.sub.11 group, a --NR.sub.11R.sub.12 group, a --NR.sub.13C(O)--(CH.sub.2).sub.n--R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--NR.sub.12R.sub.13 group, a --C(O)--(CH.sub.2).sub.1-3--CN group, a --C(O)--(CH.sub.2).sub.n--R.sub.11 group, a --C(O)--(CH.sub.2).sub.n--NR.sub.11R.sub.12 group, a --S(O).sub.2(CH.sub.2).sub.nR.sub.11 group, a --S(O).sub.2(CH.sub.2).sub.nNR.sub.11R.sub.12 group, a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nR.sub.12 group or a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nNR.sub.12R.sub.13 group, wherein each n is 0, 1 or 2, and further wherein the cycloalkyl, cycloalkenyl, aryl, heteroaryl, and heterocyclyl groups are unsubstituted or substituted by at least one substituent chosen from a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl, a phenyl group, a pyridyl group, a pyrimidinyl group, a piperidyl group or a --C(O)--(CH.sub.2).sub.n--NR.sub.11R.sub.12 group, wherein n is 0, 1 or 2; R.sub.8, R.sub.9 and R.sub.10 are independently chosen from a hydrogen atom, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group or a linear or branched C.sub.1-C.sub.6 alkyl group, wherein the alkyl group is unsubstituted or substituted by at least one substituent chosen from a C.sub.1-C.sub.4 alkoxy group, a cyano group, a C.sub.3-C.sub.7 cycloalkyl group, a phenyl group, a pyridyl group, a pyrimidinyl group or a piperidyl group; and R.sub.11, R.sub.12 and R.sub.13 are independently chosen from a hydrogen atom, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, or a linear or branched C.sub.1-C.sub.6 alkyl group, wherein the alkyl group is unsubstituted or substituted by at least one substituent chosen from a C.sub.1-C.sub.4 alkoxy group, a cyano group, a C.sub.3-C.sub.7 cycloalkyl group, a phenyl group, a pyridyl group, a pyrimidinyl group or a piperidyl group.

4. The compound according to claim 1, wherein W is chosen from a --NR.sub.8-- group or a --(CR.sub.9R.sub.10)-- group.

5. The compound according to claim 1, wherein R.sub.1 is chosen from a hydrogen atom, a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a phenyl group, a pyridyl group, a pyrimidinyl group or a piperidyl group.

6. The compound according to claim 1, wherein R.sub.2 is chosen from a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a monocyclic or bicyclic C.sub.6-C.sub.10 aryl group, a 5- to 7-membered heteroaryl group containing one, two or three heteroatoms chosen from O, S or N, or a 5- to 7-membered heterocyclyl group containing one, two or three heteroatoms chosen from O, S or N, wherein the cycloalkyl, aryl, heteroaryl, and heterocyclyl groups are unsubstituted or substituted by at least one substituent chosen from a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a monocyclic or bicyclic C.sub.6-C.sub.14 aryl group, a 5- to 14-membered heteroaryl group containing at least one heteroatom chosen, from O, S or N, a 5- to 14-membered heterocyclyi group containing at least one heteroatom chosen from O, S or N, a --(CH.sub.2).sub.1-3CN group, a --(CH.sub.2).sub.nOR.sub.11 group, a --NR.sub.11R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--NR.sub.12R.sub.13 group, a --C(O)--(CH.sub.2).sub.1-3--CN group, a --C(O)--(CH.sub.2).sub.n--R.sub.11 group, a --(CH.sub.2).sub.n'--C(O)--(CH.sub.2).sub.n--NR.sub.11R.sub.12 group, a --(CH.sub.2).sub.n'--S(O).sub.2(CH.sub.2).sub.nR.sub.11 group, a --(CH.sub.2).sub.n'--S(O).sub.2(CH.sub.2).sub.nNR.sub.11R.sub.12 group, a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nR.sub.12 group or a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nNR.sub.12R.sub.13 group, wherein each n' and n are independently 0, 1 or 2, and further wherein the monocyclic or bicyclic C.sub.6-C.sub.14 aryl group is unsubstituted or further substituted by at least one carboxyl group.

7. The compound according to claim 3, wherein R.sub.2 is chosen from a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a monocyclic or bicyclic C.sub.6-C.sub.10 aryl group, a 5- to 7-membered heteroaryl group containing one, two or three heteroatoms chosen from O, S or N, or a 5- to 7-membered heterocyclyl group containing one, two or three heteroatoms chosen from O, S or N, wherein the cycloalkyl, aryl, heteroaryl, and heterocyclyl groups are unsubstituted or substituted by at least one substituent chosen from a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a monocyclic or bicyclic C.sub.6-C.sub.14 aryl group, a 5- to 14-membered heteroaryl group containing at least one heteroatom chosen from O, S or N, a 5- to 14-membered heterocyclyl group containing at least one heteroatom chosen from O, S or N, a --(CH.sub.2).sub.1-3CN group, a --(CH.sub.2).sub.nOR.sub.11 group, a --NR.sub.11 R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--NR.sub.12R.sub.13 group, a --C(O)--(CH.sub.2).sub.1-3--CN group, a --C(O)--(CH.sub.2).sub.n--R.sub.11 group, a --C(O)--(CH.sub.2).sub.n--NR.sub.11R.sub.12 group, a --S(O).sub.2(CH.sub.2).sub.nR.sub.11 group, a --S(O).sub.2(CH.sub.2).sub.nNR.sub.11R.sub.12 group, a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nR.sub.12 group or a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nNR.sub.12R.sub.13 group, wherein each n is 0, 1 or 2, and further wherein the monocyclic or bicyclic C.sub.6-C.sub.14 aryl group is unsubstituted or further substituted by at least one carboxyl group.

8. The compound according to claim 1, wherein R.sub.3 and R.sub.4 are independently chosen from a hydrogen atom, or a linear or branched C.sub.1-C.sub.6 alkyl group, wherein the alkyl group is unsubstituted or substituted by a C.sub.1-C.sub.2 alkoxy group.

9. The compound claim 1, wherein R.sub.5 is chosen from a hydrogen atom, a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.4 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a --(CH.sub.2).sub.nOR.sub.11 group, a --NR.sub.11R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--NR.sub.12R.sub.13 group, a --C(O)--(CH.sub.2).sub.1-3--CN group, a --C(O)--(CH.sub.2).sub.n--R.sub.11 group, a --C(O)--(CH.sub.2).sub.n--NR.sub.11R.sub.12 group, a --S(O).sub.2(CH.sub.2).sub.nR.sub.11 group, a --S(O).sub.2(CH.sub.2).sub.nNR.sub.11R.sub.12 group, a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nR.sub.12 group or a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nNR.sub.12R.sub.13 group, wherein each n is 0, 1 or 2, and further wherein R.sub.11, R.sub.12 and R.sub.13 are independently chosen from a hydrogen atom, or a linear or branched C.sub.1-C.sub.3 alkyl group.

10. The compound according to claim 1, wherein R.sub.6 is chosen from a hydrogen atom, a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.4 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a monocyclic or bicyclic C.sub.6-C.sub.10 aryl group, a 5 to 7-membered heteroaryl group containing one, two or three heteroatoms chosen from O, S or N, or a 5- to 7-membered heterocyclyi group containing one, two or three heteroatoms chosen from O, S or N, and further wherein the cycloalkyl, aryl, heteroaryi and heterocyclyl groups are unsubstituted or substituted by one, two or three substituents chosen from a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl, a phenyl group, a pyridyl group, a pyrimidinyl group, a piperidyl group, or a --C(O)--(CH.sub.2).sub.n--NR.sub.11R.sub.12 group, wherein n is 0, 1 or 2, and further wherein R.sub.11 and R.sub.12 are independently chosen from a hydrogen atom, or a linear or branched C.sub.1-C.sub.3 alkyl group.

11. The compound according to claim 1, wherein R.sub.7 is chosen from a hydrogen atom, a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.4 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a monocyclic or bicyclic C.sub.6-C.sub.10 aryl group, a 5- to 7-membered heteroaryl group containing one, two or three heteroatoms chosen from O, S or N, or a 5- to 7-membered heterocyclyl group containing one, two or three heteroatoms chosen from O, S or N, wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl groups are unsubstituted or substituted by one, two or three substituents chosen from a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a phenyl group, a phenyl group substituted by a carboxyl group, a pyridyl group, a pyrimidinyl group, a piperidyl group, a --(CH.sub.2).sub.1-3CN group, a --(CH.sub.2).sub.nOR.sub.11 group, a --NR.sub.11R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--NR.sub.12R.sub.13 group, a --C(O)--(CH.sub.2).sub.1-3--CN group, a --C(O)--(CH.sub.2).sub.n--R.sub.11 group, a --C(O)--(CH.sub.2).sub.n--NR.sub.11R.sub.12 group, a --S(O).sub.2(CH.sub.2).sub.nR.sub.11 group, a --S(O).sub.2(CH.sub.2).sub.nNR.sub.11R.sub.12 group, a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nR.sub.12 group or a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nNR.sub.12R.sub.13 group, wherein each n is 0, 1 or 2, and further wherein R.sub.11, R.sub.12 and R.sub.13 are independently chosen from a hydrogen atom, or a linear or branched C.sub.1-C.sub.3 alkyl group.

12. The compound according to claim 1, wherein R.sub.8 is chosen from a hydrogen atom, or a linear or branched C.sub.1-C.sub.6 alkyl group, wherein the alkyl group is unsubstituted or substituted by a C.sub.1-C.sub.2alkoxy group.

13. The compound according to claim 1, wherein: m is 0, 1 or 2; X is a nitrogen atom and Y is a --CR.sub.6 group; or Y is a nitrogen atom and X is a --CR.sub.6 group; or X and Y are each a --CR.sub.6 group; A is a nitrogen atom, B is a --CR.sub.7 group, and D is a --CR.sub.5 group; or B is a nitrogen atom, A is a --CR.sub.7 group, and D is a --CR.sub.5 group; or both A and B are each a --CR.sub.7 group and D is nitrogen atom or a --CR.sub.5 group; W is chosen from a --NR.sub.8-- group or a --(CR.sub.9R.sub.10)-- group; R.sub.1 is chosen from a hydrogen atom, a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a phenyl group, a pyridyl group, a pyrimidinyl group or a piperidyl group; R.sub.2 is chosen from a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a monocyclic or bicyclic C.sub.6-C.sub.10aryl group, a 5- to 7-membered heteroaryl group containing one, two or three heteroatoms chosen from O, S or N, or a 5- to 7-membered heterocyclyl group containing one, two or three heteroatoms chosen from O, S or N, wherein the cycloalkyl, aryl, heteroaryl, and heterocyclyl groups are unsubstituted or substituted by at least one substituent chosen from a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a monocyclic or bicyclic C.sub.6-C.sub.14 aryl group, a 5- to 14-membered heteroaryl group containing at least one heteroatom chosen from O, S or N, a 5- to 14-membered heterocyclyl group containing at least one heteroatom chosen from O, S or N, a --(CH.sub.2).sub.1-3CN group, a --(CH.sub.2).sub.nOR.sub.11 group, a --NR.sub.11R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--R group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--NR.sub.12R.sub.13 group, a --C(O)--(CH.sub.2).sub.1-3--CN group, a --C(O)--(CH.sub.2).sub.n--R.sub.11 group, a --(CH.sub.2).sub.n'--C(O)--(CH.sub.2).sub.n--NR.sub.11R.sub.12 group, a --(CH.sub.2).sub.n'--S(O).sub.2(CH.sub.2).sub.nR.sub.11 group, a --(CH.sub.2).sub.n'--S(O).sub.2(CH.sub.2).sub.nNR.sub.11R.sub.12 group, a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nR.sub.12 group or a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nNR.sub.12R.sub.13 group, wherein each n' and n are independently 0, 1 or 2, and the monocyclic or bicyclic C.sub.6-C.sub.14 aryl group is unsubstituted or further substituted by at least one carboxyl group; R.sub.3 and R.sub.4 are independently chosen from a hydrogen atom, or a linear or branched C.sub.1-C.sub.6 alkyl group, wherein the alkyl group is unsubstituted or substituted by a C.sub.1-C.sub.2 alkoxy group; R.sub.5 is chosen from a hydrogen atom, a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.4 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a --(CH.sub.2).sub.nOR.sub.11 group, a --NR.sub.11R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--NR.sub.12R.sub.13 group, a --C(O)--(CH.sub.2).sub.1-3--CN group, a --C(O)--(CH.sub.2).sub.n--R.sub.11 group, a --C(O)--(CH.sub.2).sub.n--NR.sub.11R.sub.12 group, a --S(O).sub.2(CH.sub.2).sub.nR.sub.11 group, a --S(O).sub.2(CH.sub.2).sub.nNR.sub.11R.sub.12 group, a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nR.sub.12 group or a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nNR.sub.12R.sub.13 group, wherein each n is 0, 1 or 2; R.sub.6 is chosen from a hydrogen atom, a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.4 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a monocyclic or bicyclic C.sub.6-C.sub.10 aryl group, a 5- to 7-membered heteroaryl group containing one, two or three heteroatoms chosen from O, S or N, or a 5- to 7-membered heterocyclyl group containing one, two or three heteroatoms chosen from O, S or N, wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl groups are unsubstituted or substituted by one, two or three substituents chosen from a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl, a phenyl group, a pyridyl group, a pyrimidinyl group, a piperidyl group, or a --C(O)--(CH.sub.2).sub.n--NR.sub.11R.sub.12 group, wherein n is 0, 1 or 2; R.sub.7 is chosen from a hydrogen atom, a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.4 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a monocyclic or bicyclic C.sub.6-C.sub.10 aryl group, a 5- to 7-membered heteroaryl group containing one, two or three heteroatoms chosen from O, S or N, or a 5- to 7-membered heterocyclyl group containing one, two or three heteroatoms chosen from O, S or N, wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl groups are unsubstituted or substituted by one, two or three substituents chosen from a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a phenyl group, a phenyl group substituted by a carboxyl group, a pyridyl group, a pyrimidinyl group, a piperidyl group, a --(CH.sub.2).sub.1-3CN group, a --(CH.sub.2).sub.nOR.sub.11group, a --NR.sub.11R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--NR.sub.12R.sub.13 group, a --C(O)--(CH.sub.2).sub.1-3--CN group, a --C(O)--(CH.sub.2).sub.n--R.sub.11 group, a --C(O)--(CH.sub.2).sub.n--NR.sub.11R.sub.12 group, a --S(O).sub.2(CH.sub.2).sub.nR.sub.1l group, a --S(O).sub.2(CH.sub.2).sub.nNR.sub.11R.sub.12 group, a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nR.sub.12 group or a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nNR.sub.12R.sub.13 group, wherein each n is 0, 1 or 2: R.sub.8 is chosen from a hydrogen atom, or a linear or branched C.sub.1-C.sub.6 alkyl group, wherein the alkyl group is unsubstituted or substituted by a C.sub.1-C.sub.2 alkoxy group; R.sub.9 and R.sub.10 are independently chosen from a hydrogen atom, or a linear or branched C.sub.1-C.sub.3 alkyl group; and R.sub.11, R.sub.12 and R.sub.13 are independently chosen from a hydrogen atom, a linear or branched C.sub.1-C.sub.3 alkyl group, or a 5- to 7-membered heterocyclyl group containing one, two or three heteroatoms chosen from O, S or N, wherein the heterocyclyl group is unsubstituted or substituted by one, two or three substituents chosen from a halogen atom, a hydroxyl group, a linear or branched C.sub.1-C.sub.4 alkyl group, a C.sub.1-C.sub.4 haloalkyl group or a C.sub.1-C.sub.4 hydroxyalkyl group.

14. The compound according to claim 13, wherein: X and Y are each a --CR.sub.6 group.

15. The compound according to claim 14, wherein: m is 0 or 1; R.sub.1 is chosen from a hydrogen atom, a linear or branched C.sub.1-C.sub.3 alkyl group, a C.sub.1-C.sub.3 haloalkyl group or a C.sub.1-C.sub.3 hydroxyalkyl group; R.sub.2 is chosen from a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a phenyl group, a pyridyl group, a pyrimidinyl group, a triazolyl group, a thiazolyl group, a pyrrolidinyl group or a piperidyl group, wherein the cycloalkyl, phenyl, pyridyl, pyrimidinyl, triazolyl, thiazolyl, pyrrolidinyl or piperidyl groups are unsubstituted or substituted by one, two or three substituents chosen from a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a phenyl group, a phenyl group substituted by a carboxyl group, a pyridyl group, a triazolyl group, a thiazolyl group, a pyrimidinyl group, a piperidyl group, a --(CH.sub.2).sub.nOR.sub.11 group, a --NR.sub.11R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--NR.sub.12R.sub.13 group, a --C(O)--(CH.sub.2).sub.1-3--CN group, a --C(O)--(CH.sub.2).sub.n--R.sub.11 group, a --(CH.sub.2).sub.n'--C(O)--(CH.sub.2).sub.n--NR.sub.11R.sub.12 group, a --(CH.sub.2).sub.n'--S(O).sub.2(CH.sub.2).sub.nR.sub.11 group, a --(CH.sub.2).sub.n'--S(O).sub.2(CH.sub.2).sub.nNR.sub.11R.sub.12 group, a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nR.sub.12 group or a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nNR.sub.12R.sub.13 group, wherein each n' and n are independently 0, 1 or 2; R.sub.3 and R.sub.4 are independently chosen from a hydrogen atom, or a linear or branched C.sub.1-C.sub.3 alkyl group; R.sub.5 is chosen from a hydrogen atom, a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.3 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a --(CH.sub.2).sub.nOR.sub.11 group, a --NR.sub.11R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--NR.sub.12R.sub.13 group, a --C(O)--(CH.sub.2).sub.1-3--CN group, a --C(O)--(CH.sub.2).sub.n--R.sub.11 group, a --C(O)--(CH.sub.2).sub.n--NR.sub.11R.sub.12 group, a --S(O).sub.2(CH.sub.2).sub.nR.sub.11 group, a --S(O).sub.2(CH.sub.2).sub.nNR.sub.11R.sub.12 group, a --NR.sub.11S(O).sub.2(CH.sub.2).sub.n--R.sub.12 group or a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nNR.sub.12R.sub.13 group, wherein each n is 0, 1 or 2; R.sub.6 is chosen from a hydrogen atom, a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.3 alkyl group, a C.sub.1-C4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a phenyl group, a pyridyl group, a pyrimidinyl group, a pyrazolyl group, a pyrrolidinyl group, a piperidyl group, a tetrahydropyranyl group or a morpholinyl group; R.sub.7 is chosen from a hydrogen atom, a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.3 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a phenyl group, a pyridyl group, a pyrimidinyl group, a triazolyl group, a thiazolyl group, a pyrrolidinyl group, a piperidyl group, a tetrahydropyranyl group or a morpholinyl group, wherein the cycloalkyl, phenyl, pyridyl, pyrimidinyl, triazolyl, thiazolyl, pyrrolidinyl, piperidyl, tetrahydropyranyl or morpholinyl groups are unsubstituted or substituted by one, two or three substituents chosen from a halogen atom, a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C-.sub.7 cycloalkyl group, a phenyl group, a phenyl group substituted by at least one substituent chosen from a carboxyl group, a pyridyl group, a triazolyl group, a thiazolyl group, a pyrimidinyl group, a piperidyl group, a --(CH.sub.2).sub.nOR.sub.11 group, a --NR.sub.11R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--NR.sub.12R.sub.13 group, a --C(O)--(CH.sub.2).sub.1-3--CN group, a --C(O)--(CH.sub.2).sub.n--R.sub.12 group, a --C(O)--(CH.sub.2).sub.n--NR.sub.11R.sub.12 group, a --S(O).sub.2(CH.sub.2).sub.nR.sub.12 group, a --S(O).sub.2(CH.sub.2).sub.nNR.sub.11R.sub.12 group, a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nR.sub.12 group or a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nNR.sub.12R.sub.13 group, wherein each n is 0, 1 or 2; and R.sub.8 is chosen fro hydrogen atom or a linear or branched C.sub.1-C.sub.3 alkyl group.

16. The compound according to claim 1, wherein: m is 0 or 1; X and Y are each a --CR.sub.6 group; A is a nitrogen atom, B is a --CR.sub.7 group and D is a --CR.sub.5 group; or B is a nitrogen atom, A is a --CR.sub.7 group and D is a --CR.sub.5 group; or A and B are each a --CR.sub.7 group and D is nitrogen atom or a --CR.sub.5 group; W is chosen from a --NH-- group or a --CH.sub.2-- group; R.sub.1 is a hydrogen atom; R.sub.2 is chosen from a cyclohexyl group, a pyridyl group or a piperidyl group, wherein the cyclonexyl, pyridyl and piperidyl groups are unsubstituted or substituted by one, two or three substituents chosen from a halogen atom, a triazolyl group, a --(CH.sub.2).sub.1-3CN group, --C(O)--(CH.sub.2).sub.1-3--CN group or a --(CH.sub.2)--S(O).sub.2-pyrimidinyl group, wherein the pyrimidinyl is unsubstituted or substituted by one, two or three hydroxyl groups; R.sub.3 and R.sub.4 are independently chosen from a hydrogen atom or a methyl group; R.sub.5 is chosen from a hydrogen atom, a halogen atom, a hydroxyl group, a linear or branched C.sub.1-C.sub.3 alkyl group, a --OCH.sub.3 group or a --C(O)--(CH.sub.2).sub.n--NR.sub.11R.sub.12 group, wherein n is 0 or 1, and further wherein R.sub.11 and R.sub.12 are independently chosen from a hydrogen atom, or a linear or branched C.sub.1-C.sub.3 alkyl group; R.sub.6 is chosen from a hydrogen atom, a halogen atom or a pyrazolyl group; and R.sub.7 is chosen from a hydrogen atom, piperidyl group, a thiazolyl group or a morpholinyl group, wherein the piperidyl, thiazolyl and morpholinyl groups are unsubstituted or substituted by one or two substituents chosen from a hydroxyl group or a benzoic acid.

17. The compound according to claim 3, wherein: m is 0, 1 or 2; X is a nitrogen atom and Y is a --CR.sub.6 group; or Y is a nitrogen atom and X is a --CR.sub.6 group; or X and Y are each a --CR.sub.6 group; A is a nitrogen atom and B is a --CR.sub.7 group; or B is a nitrogen atom and A is a --CR.sub.7 group; or A and B are each a --CR.sub.7group; W is chosen from a --NR.sub.8-- group or a --(CR.sub.9R.sub.10)--group; R.sub.1is chosen from a hydrogen atom, a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a phenyl group, a pyridyl group, a pyrimidinyl group or a piperidyl group; R.sub.2 is chosen from a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a monocyclic or bicyclic C.sub.6-C.sub.10 aryl group, a 5- to 7-membered heteroaryl group containing one, two or three heteroatoms chosen from O, S or N, or a 5- to 7-membered heterocyclyl group containing one, two or three heteroatoms chosen from O, S or N, wherein the cycloalkyl, aryl, heteroaryl, and heterocyclyl groups are unsubstituted or substituted by at least one substituent chosen from a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a monocyclic or bicyclic C.sub.6-C.sub.14 aryl group, a 5- to 14-membered heteroaryl group containing at least one heteroatom chosen from O, S or N, a 5- to 14-membered heterocyclyl group containing at least one heteroatom chosen from O, S or N, a --(CH.sub.2).sub.1-3CN group, a --(CH.sub.2).sub.nOR.sub.11 group, a --NR.sub.11R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--NR.sub.12R.sub.13 group, a --C(O)--(CH.sub.2).sub.1-3--CN group, a --C(O)--(CH.sub.2).sub.n--R.sub.11 group, a --C(O)--(CH.sub.2).sub.n--NR.sub.11R.sub.12 group, a --S(O).sub.2(CH.sub.2).sub.nR.sub.11 group, a --S(O).sub.2(CH.sub.2).sub.nNR.sub.11R.sub.12 group, a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nR.sub.12 group or a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nNR.sub.12R.sub.13 group, wherein each n is 0, 1 or 2, and the monocyclic or bicyclic C.sub.6-C.sub.14 aryl group is unsubstituted or further substituted by at least one carboxyl group; R.sub.3 and R.sub.4 are independently chosen from a hydrogen atom, or a linear or branched C.sub.1-C.sub.6 alkyl group, wherein the alkyl group is unsubstituted or substituted by a C.sub.1-C.sub.2 alkoxy group; R.sub.5 is chosen from a hydrogen atom, a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.4 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a --(CH.sub.2).sub.nOR.sub.11 group, a --NR.sub.11R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--NR.sub.12R.sub.13 group, a --C(O)--(CH.sub.2).sub.1-3--CN group, a --C(O)--(CH.sub.2).sub.n--R.sub.11 group, a --C(O)--(CH.sub.2).sub.n--NR.sub.11R.sub.12 group, a --S(O).sub.2(CH.sub.2).sub.nR.sub.11 group, a --S(O).sub.2(CH.sub.2).sub.nNR.sub.11R.sub.12 group, a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nR.sub.12 group or a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nNR.sub.12R.sub.13 group, wherein each n is 0, 1 or 2; R.sub.6 is chosen from a hydrogen atom, a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.4 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a monocyclic or bicyclic C.sub.6-C.sub.10 aryl group, a 5- to 7-membered heteroaryl group containing one, two or three heteroatoms chosen from O, S or N, or a 5- to 7-membered heterocyclyl group containing one, two or three heteroatoms chosen from O, S or N, wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl groups are unsubstituted or substituted by one, two or three substituents chosen from a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl, a phenyl group, a pyridyl group, a pyrimidinyl group, a piperidyl group, or a --C(O)--(CH.sub.2).sub.nNR.sub.11R.sub.12 group, wherein n is 0, 1 or 2; R.sub.7 is chosen from a hydrogen atom, a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.4 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a monocyclic or bicyclic C.sub.6-C.sub.10 aryl group, a 5- to 7-membered heteroaryl group containing one, two or three heteroatoms chosen from O, S or N, or a 5- to 7-membered heterocyclyl group containing one, two or three heteroatoms chosen from O, S or N, wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl groups are unsubstituted or substituted by one, two or three substituents chosen from a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a phenyl group, a phenyl group substituted by a carboxyl group, a pyridyl group, a triazolyl group, a thiazolyl group, a pyrimidinyl group, a piperidyl group, a --(CH.sub.2).sub.1-3CN group, a --(CH.sub.2).sub.nOR.sub.11 group, a --NR.sub.11R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--NR.sub.12R.sub.13 group, a --C(O)--(CH.sub.2).sub.1-3--CN group, a --C(O)--(CH.sub.2).sub.n--R.sub.11 group, a --C(O)--(CH.sub.2).sub.n--NR.sub.11R.sub.12 group, a --S(O).sub.2(CH.sub.2).sub.nR.sub.11 group, a --S(O).sub.2(CH.sub.2).sub.nNR.sub.11R.sub.12 group, a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nR.sub.12group or a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nNR.sub.12R.sub.13 group, wherein each n is 0, 1 or 2; R.sub.8 is chosen from a hydrogen atom, or a linear or branched C.sub.1-C.sub.6 alkyl group, wherein the alkyl group is unsubstituted or substituted by a C.sub.1-C.sub.2 alkoxy group; R.sub.9 and R.sub.10 are independently chosen from a hydrogen atom, or a linear or branched C.sub.1-C.sub.3 alkyl group; and R.sub.11, R.sub.12 and R.sub.13 are independently chosen from a hydrogen atom, or a linear or branched C.sub.1-C.sub.3 alkyl group.

18. The compound according to claim 17, wherein: m is 0 or 1: X and Y p are each a --CR.sub.6 group; R.sub.1 is chosen from a hydrogen atom, a linear or branched C.sub.1-C.sub.3 alkyl group, a C.sub.1-C.sub.3 haloalkyl group, or a C.sub.1-C.sub.3 hydroxyalkyl group; R.sub.2 is chosen from a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4. hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a phenyl group, a pyridyl group, a pyrimidinyl group, a triazolyl group, a thiazolyl group, a pyrrolidinyl group or a piperidyl group; wherein the cycloalkyl, phenyl, pyridyl, pyrimidinyl, triazolyl, thiazolyl, pyrrolidinyl or piperidyl groups are unsubstituted or substituted by one, two or three substituents chosen from a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a phenyl group, a phenyl group substituted by a carboxyl group, a pyridyl group, a triazolyl group, a thiazolyl group, a pyrimidinyl group, a piperidyl group, a --(CH.sub.2).sub.n--OR.sub.11 group, a --NR.sub.11 R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--NR.sub.12R.sub.13 group, a --C(O)--(CH.sub.2).sub.1-3--CN group, a --C(O)--(CH.sub.2).sub.n--R.sub.11 group, a --C(O)--(CH.sub.2).sub.n--NR.sub.11R.sub.12 group, a --S(O).sub.2(CH.sub.2).sub.nR.sub.11 group, a --S(O).sub.2(CH.sub.2).sub.nNR.sub.11R.sub.12 group, a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nR.sub.12 group or a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nNR.sub.12R.sub.13 group, wherein each n is 0, 1 or 2; R.sub.3 and R.sub.4 are independently chosen from a hydrogen atom, or a linear or branched C.sub.1-C.sub.3 alkyl group; R.sub.5 is chosen from a hydrogen atom, a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.3 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a --(CH.sub.2).sub.nOR.sub.11 group, a --NR.sub.11R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--NR.sub.12R.sub.13 group, a --C(O)--(CH.sub.2).sub.1-3--CN group, a --C(O)--(CH.sub.2).sub.n--R.sub.11 group, a --C(O)--(CH.sub.2).sub.n--NR.sub.11R.sub.12 group, a --S(O).sub.2(CH.sub.2).sub.nR.sub.11 group, a --S(O).sub.2(CH.sub.2).sub.nNR.sub.11R.sub.12 group, a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nR.sub.12 group or a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nNR.sub.12R.sub.13 group, wherein each n is 0, 1 or 2; R.sub.6 is chosen from a hydrogen atom, a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.3 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a phenyl group, a pyridyl group, a pyrimidinyl group, a pyrrolidinyl group, a piperidyl group, a tetrahydropyranyl group or a morpholinyl group; R.sub.7 is chosen from a hydrogen atom, a halogen atom, a cyano group, a linear or branched C.sub.1-C.sub.3 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a phenyl group, a pyridyl group, a pyrimidinyl group, a triazolyl group, a thiazolyl group, a pyrrolidinyl group, a piperidyl group, a tetrahydropyranyl group or a morpholinyl group, wherein the cycloalkyl, phenyl, pyridyl, pyrimidinyl, triazolyl, thiazolyl, pyrrolidinyl, piperidyl, tetrahydropyranyl or morpholinyl groups are unsubstituted or substituted by one, two or three substituents chosen from a halogen atom, a linear or branched C.sub.1-C.sub.6 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a phenyl group, a phenyl group substituted by a carboxyl group, a pyridyl group, a triazolyl group, a thiazolyl group, a pyrimidinyl group, a piperidyl group, a --(CH.sub.2).sub.nOR.sub.11 group, a --NR.sub.11R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--R.sub.12 group, a --NR.sub.11C(O)--(CH.sub.2).sub.n--NR.sub.12R.sub.13 group, a --C(O)--(CH.sub.2).sub.1-3--CN group, a --C(O)--(CH.sub.2).sub.n--R.sub.12 group, a --C(O)--(CH.sub.2).sub.n--NR.sub.11R.sub.12 group, a --S(O).sub.2(CH.sub.2).sub.nR.sub.12 group, a --S(O).sub.2(CH.sub.2).sub.nNR.sub.11R.sub.12 group, a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nR.sub.12 group or a --NR.sub.11S(O).sub.2(CH.sub.2).sub.nNR.sub.12R.sub.13 group, wherein each n is 0, 1 or 2; R.sub.8 is chosen from a hydrogen atom or a linear or branched C.sub.1-C.sub.3 alkyl group.

19. The compound according to claim 3, wherein: m is 0 or 1; X and Y are each a --CR.sub.6 group; A is a nitrogen atom and B is a --CR.sub.7 group; or B is a nitrogen atom and A is a --CR.sub.7 group; or A and B are each a --CR.sub.7 group; W is chosen from a --NH-- group or a --CH.sub.2-- group; R.sub.1 is a hydrogen atom; R.sub.2 is chosen from a cyclohexyl group, a pyridyl group or a piperidyl group, wherein the cyclohexyl, pyridyl and piperidyl groups are unsubstituted or substituted by one, two or three substituents chosen from a halogen atom, a triazolyl group, a --(CH.sub.2).sub.1-3CN group or --C(O)--(CH.sub.2).sub.1-3--CN group; R.sub.3 and R.sub.4 are independently chosen from a hydrogen atom or a methyl group; R.sub.5 is chosen from a hydrogen atom, a halogen atom, a linear or branched C.sub.1-C.sub.3 alkyl group or a --C(O)--(CH.sub.2).sub.n--NR.sub.11R.sub.12 group, wherein n is 0 or 1, and further wherein R.sub.11 and R.sub.12 are independently chosen from a hydrogen atom, or a linear or branched C.sub.1-C.sub.3 alkyl group; R.sub.6 is chosen from a hydrogen atom or a halogen atom; and R.sub.7 is chosen from a hydrogen atom.sub.; piperidyl group, a thiazolyl group or a morpholinyl group; wherein the piperidyl, thiazolyl and morpholinyl groups are unsubstituted or substituted by one or two substituents chosen from a hydroxy group or a benzoyl group.

20. The compound according to claim 1 chosen from: (S)-3-(4-(1-(5-fluoropyridin-2-yl)ethylamino)pyrimidin-2-ylamino pyridin-2(1H)-one; (S)-3-(4-(1-(5-fluoropyridin-2-yl)ethylamino)-5-methylpyrimidin-2-ylamino- )pyridin-2(1H)-one; (S)-3-(5-chloro-4-(1-(5-fluoropyridin-2-yl)ethylamino)pyrimidin-2-ylamino- )pyridine2(1H)-one; (S)-3-(4-(1-(5-fluoropyridin-2-yl)ethylamino)-5-methoxypyrimidin-2-ylamin- o)pyridin-2(1H)-one; (S)-3-(4-(1-(5-fluoropyridin-2-yl)ethylamino)-5-hydroxypyrimidin-2-ylamin- o)pyridin-2(1H)-one; (S)-4-(1-(5-fluoropyridin-2-yl)ethylamino)-2-(2-oxo-1,2-dihydropyridin-3-- ylamino)pyrimidine-5-carboxamide; (S)-5-chloro-3-(4-(1-(5-fluoropyridin-2-yl)ethylamino)-5-methylpyrimidin-- 2-ylamino)pyridin-2(1H)-one; (S)-3-(4-(1-(5-fluoropyridin-2-yl)ethylamino)-5-methylpyrimidin-2-ylamino- )-5-(1H-pyrazol-4-yl)pyridin-2(1H)-one; (S)-3-(4-(1-(5-fluoropyridin-2-yl)ethylamino)-6-(4-hydroxypiperidin-1-yl)- pyrimidin-2-ylamino)pyridin-2(1H)-one; (S)-3-(5-fluoro-4-(1-(5-fluoropyridin-2-yl)ethylamino)-6-morpholinopyrimi- din-2-ylamino)pyridin-2(1H)-one; (S)-3-(6-(1-(5-fluoropyridin-2-yl)ethylamino)pyrazin-2-yiamino)pyridin-2(- 1H)-one; (S)-3-(6-(1-(5-fluoropyridin-2-)ethylamino)pyridin-2-ylamino)pyri- din-2(1H)-one; 2-((1R,4R)-4-(5-methyl-2-(2-oxo-1,2-dihydropyridin-3-ylamino)pryimidin-4-- ylamino)cyclohexy)acetonitrile; 3-(4-((1R,4R)-4-((3-hydroxypiperdin-1-ylsufonyl)methyl)cyclohexylamino)py- rimidin-2-ylamino)pyridin-2(1H)-one; (R)-3-oxo-3-(3-(2-(2-oxo-1,2-dihydropyridin-3-ylamino)pyrimidin-4-ylamino- )piperidin-1-yl)propanenitrile; (R)-3-(3-(5-methyl-2-(2-oxo-1,2-dihydropyridin-3-ylamino)pyrimidin-4-ylam- ino)piperidin-1-yl)-3-oxopropanenitrile; (R)-3-(3-(5-fluoro-2-(2-oxo-1,2-dihydropyridin-3-ylamino)pyrimidin-4-ylam- ino)piperidin-1-yl)-3-oxopropanenitrile; (R)-3-(4-(1-(4H-1,2,4-triazol-3-yl)piperidin-3-ylamino)-5-fluoropyrimidin- -2-ylamino)pyridin-2(1H)-one; (R)-3-(3-(2-(5-chloro-2-oxo-1,2-dihydropyridin-3-ylamino)-5-methylpyrimid- in-4-ylamino)piperidin-1-yl)-3-oxopropanenitrile; (R)-3-(3-(5-fluoro-6-morpholino-2-(2-oxo-1,2-dihydropyridin-3-ylamino)pyr- imidin-4-ylamino)piperidin-1-yl)-3-oxopropanenitrile; (R)-3-(3-(5-methyl-6-morpholino-2-(2-oxo-1,2-dihydropyridin-3-ylamino)pyr- imidin-4-ylamino)piperidin-1-yl)-3-oxopropanenitrile; (R)-3-(3-(5-methyl-4-morpholino-6-(2-oxo-1,2-dihydropyridin-3-ylamino)pyr- imidin-2-ylamino)piperidin-1-yl)-3-oxopropanenitrile; (R)-3-(3-(4-(5-chloro-2-oxo-1,2-dihydropyridin-3-ylamino)-5-methyl-6-morp- holinopyrimidin-2-ylamino)piperidin-1-yl)-3-oxopropanenitrile; (R)-3-(3-(5-chioro-2-(2-oxo-1,2-dihydropyridin-3-ylamino)pyrimidin-4-ylam- ino)piperidin-1-yl)-3-oxopropanenitrile; 3-[(4-{[(1S)-1-(5-Fluoropyridin-2-yl)ethyl]amino}pyrimidin-2-yl)methyl]py- ridin-2(1H)-one; and (S)-3-(5-(6-(1-(5-fluoropyridin-2-yl)ethylamino)-2-(2-oxo-1,2-dihydropyri- din-3-ylamino)pyrimidin-4-yl)thiazol-2-yl)benzoic acid; or a pharmaceutically acceptable salt, solvate, N-oxide, stereoisomer or deuterated derivative thereof.

21. A pharmaceutical composition comprising a compound according to claim 1 and at least one pharmaceutically acceptable diluent or carrier.

22. A combination product comprising (i) a compound according to claim 1; and (ii) at least one additional compound chosen from: a) Dyhydrofolate reductase inhibitor; b) Dihydroorotate dehydrogenase (DHODH) inhibitor; c) Immunomodulators; d) Inhibitor of DNA synthesis and repair; e) Immunosuppressants; f) Anti-alpha 4 integrin antibodies; g) Alpha 4 integrin antagonist; h) Corticoids and/or glucocorticoid; i) Fumaric acid esters; j) Anti-tumor necrosis factor-alpha (Anti-TNF-alpha), k) Soluble Tumor necrosis factor-alpha (TNF-alpha) receptors, l) Anti-CD20 (lymphocyte protein) monoclonal antibodies, m) Anti-CD52 (lymphocyte protein) monoclonal antibodies; n) Anti-CD25 (lymphocyte protein) antibodies; o) Anti-CD88 (lymphocyte protein) antibodies; p) Anti-Interleukin 6 Receptor (IL-6R) antibodies; q) Anti-Interleukin 12 Receptor (IL-12R)/Interleukin 23 Receptor (IL-23R) antibodies; r) Caicineurin inhibitor; s) Inosine monophosphate dehydrogenase (IMPDH) inhibitor; t) Cannabinoid receptor agonist; u) Chemokine CCR1 antagonist; v) Chemokine CCR2 antagonist; w) Necrosis factor-kappaB (NF-kappaB or NFKB) Activation inhibitor; x) Adenosine A.sub.2A agonist; y) Sphingosine-1 (S1P) phosphate receptor agonist; z) Sphingosine-1 (S1P) liase inhibitor; aa) Spleen tyrosine kinase (Syk) inhibitor; bb) Protein Kinase (PKC) inhibitor; cc) Anti-cholinergic agent; dd) Beta adrenergic agonist; ee) A compound having bifunctional Muscarinic Antagonist-Beta2 Agonist activity (MABAs); ff) Histamine 1 (H1) receptor antagonist; gg) Chemoattractant receptor homologous molecule expressed on TH.sub.2 cells (CRTH2) inhibitor; hh) Vitamin D derivative; ii) Anti-inflammatory agent chosen from non-steroidal anti-inflammatory drugs (NSAIDs) or selective cyclooxygenase-2 (COX-2) inhibitors; jj) Anti-allergic agent; kk) Anti-viral agent; ll) Phosphodiestearase (PDE) III inhibitor; mm) Phosphosdiesterase (PDE) IV inhibitor; nn) Dual Phosphodiestearase (PDE) III/IV inhibitor; oo) Xanthine derivative; pp) p38 Mitogen-Activated Protein Kinase (p38 MAPK) inhibitor; qq) Mitogen-activated extracellular signal regulated kinase kinase (MEK) inhibitor; rr) Phosphoinositide 3-Kinases (PI3Ks) inhibitor; ss) Interferons comprising Interferon beta 1a and Interferon beta 1b; or tt) Interferon alpha.

23. The compound according to claim 4, wherein W is a --NR.sub.8-- group.

24. The compound according to claim 5, wherein R.sub.1 is chosen from a hydrogen atom, a linear or branched C.sub.1-C.sub.4 alkyl group, a C.sub.1-C.sub.4 haloalkyl group, a C.sub.1-C.sub.4 hydroxyalkyl group, a C.sub.3-C.sub.7 cycloalkyl group, a phenyl group, or a pyridyl group.

25. The compound according to claim 5, wherein R.sub.1 is chosen from hydrogen atom, a linear or branched C.sub.1-C.sub.3 alkyl group, a C.sub.1-C.sub.3 haloalkyl group, or a C.sub.1-C.sub.3 hydroxyalkyl group.

26. The compound according to claim 5, wherein R.sub.1 is hydrogen atom.

27. The compound according to claim 8, wherein of R.sub.3 and R.sub.4 are independently chosen from a hydrogen atom, or a linear or branched C.sub.1-C.sub.3 alkyl group.

28. The compound according to claim 8, wherein R.sub.3 and R.sub.4 are independently chosen from a hydrogen atom or a methyl group.

29. The compound according to claim 12, wherein R.sub.8 is chosen from a hydrogen atom, or a linear or branched C.sub.1-C.sub.3 alkyl group.

30. The compound according to claim 12, wherein R.sub.8 is a hydrogen atom.

31. The compound according to claim 13, wherein W is a --NR.sub.8-- group.

32. The compound according to claim 16, wherein W is a --NH-- group.

33. The combination product according to claim 28, wherein a) the Dyhydrofolate reductase inhibitor is chosen from Methotrexate or CH-1504; b) the Dihydroorotate dehydrogenase (DHODH) inhibitor is chosen from leflunomide, or teriflunomide; c) the Immunomodulators is chosen from Glatiramer acetate (Copaxone), Laquinimod, or Imiquimod; d) the Inhibitor of DNA synthesis and repair is chosen from Mitoxantrone or Cladribine; e) the Immunosuppressant is chosen from azathioprine or 6-mercaptopurine; f) the Anti-alpha 4 integrin antibodies is Natalizumab (Tysabri); g) the Alpha 4 integrin antagonist is chosen from R-1295, TBC-4746, CDP-323, ELND-002, Firategrast, or TMC-2003; h) the Corticoids and glucocorticoids are chosen from prednisone, methylprednisolone, fluticasone, mometasone, budesonide, ciclesonide, or beta-metasone; i) the Fumaric acid esters is BG-12; j) the anti-tumor necrosis factor-alpha (Anti-TNF-alpha) is chosen from Infliximab, Adalimumab, or Certolizumab pegol, k) the soluble Tumor necrosis factor-alpha (TNF-alpha) receptor is Etanercept, l) the anti-CD20 (lymphocyte protein) monoclonal antibodies are chosen from Rituximab, Ocrelizumab Ofatumumab, or TRU-015, m) the anti-CD52 (lymphocyte protein) monoclonal antibodies are alemtuzumab; n) the anti-CD25 (lymphocyte protein) antibodies are daclizumab; o) the anti-CD88 (lymphocyte protein) antibodies are chosen from eculizumab or pexilizumab; p) the Anti-Interleukin 6 Receptor (IL-6R) antibodies are tocilizumab; q) the Anti-interleukin 12 Receptor (IL-12R)/Interleukin 23 Receptor (IL-23R) antibodies are ustekinumab; r) the Calcineurin inhibitor is chosen from cyclosporine A or tacrolimus; s) the Inosine-monophosphate dehydrogenase (IMPDH) inhibitor is chosen from mycophenolate mophetyl, ribavirin, mizoribine, or mycophenolic acid; t) the Cannabinoid receptor agonist is Sativex; u) the Chemokine CCR1 antagonist is chosen from MLN-3897 or PS-031291; v) the Chemokine CCR2 antagonist is INCB-8696; w) the Necrosis factor-kappaB (NF-kappaB or NFKB) Activation Inhibitor is chosen from Sulfasalazine, Iguratimod, or MLN-0415; x) Adenosine A.sub.2A agonist is chosen from ATL-313, ATL-146e, CGS-21680, Regadenoson, or UK-432,097; y) Sphingosine-1 (S1P) phosphate receptor agonist is chosen from fingolimod, BAF-312, or ACT128800; z) the Sphingosine-1 (S1P) liase inhibitor is LX2931; aa) the Spleen tyrosine kinase (Syk) inhibitor is R-112; bb) the Protein Kinase (PKC) inhibitor is NVP-AEB071; cc) the Anti-cholinergic agent is chosen from tiotropium or aclidinium; dd) the Beta adrenergic agonist is chosen from formoterol, indacaterol or abediterol; ee) the Histamine 1 (H1) receptor antagonist is chosen from azelastine or ebastine; ff) the Chemoattractant receptor homologous molecule expressed on TH.sub.2 cells (CRTH2) inhibitor is chosen from OC-459, AZD-1981, ACT-129968, or QAV-680; gg) the Vitamin D derivative is calcipotriol (Daivonex); hh) the non-steroidal anti-inflammatory drugs (NSAIDs) or selective cyclooxygenase-2 (COX-2) inhibitors are chosen from aceclofenac, diclofenac, ibuprofen, naproxen, apricoxib, celecoxib, cimicoxib, deracoxib, etoricoxib, lumiracoxib, parecoxib sodium, rofecoxib, selenocoxib-1 or valdecoxib; ii) the phosphosdiesterase (PDE) IV inhibitor is chosen from roflumilast or GRC-4039; jj) the Xanthine derivative is chosen from theophylline or theobromine; kk) the p38 Mitogen-Activated Protein Kinase (p38 MAPK) Inhibitor is ARRY-797; ll) the Mitogen-activated extracellular signal regulated kinase kinase (MEK) inhibitor is chosen from ARRY-142886 or ARRY-438162; mm) the Interferons comprising Interferon beta 1a and Interferon beta 1b, wherein the Interferon beta 1a is chosen from Avonex, CinnoVex, or Rebif; and the Interferon beta 1b is chosen from Betaferon or Betaseron; and nn) the Interferon alpha is Sumiferon MP.

Summary for Patent:   See Pricing

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
11382263Aug 1, 2011
PCT Information
PCT FiledJuly 23, 2012PCT Application Number:PCT/EP2012/064426
PCT Publication Date:February 07, 2013PCT Publication Number:WO2013/017461

Details for Patent 9,034,311

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Bayer Healthcare Pharms BETASERON interferon beta-1b VIAL; SUBCUTANEOUS 103471 001 1993-07-23   See Pricing ALMIRALL, S.A. (Barcelona, ES) 2031-08-01 RX Orphan search
Biogen AVONEX interferon beta-1a VIAL 103628 001 1996-05-17   See Pricing ALMIRALL, S.A. (Barcelona, ES) 2031-08-01 RX search
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26   See Pricing ALMIRALL, S.A. (Barcelona, ES) 2031-08-01 RX search
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   See Pricing ALMIRALL, S.A. (Barcelona, ES) 2031-08-01 RX Orphan search
Serono Inc REBIF interferon beta-1a SYRINGE 103780 001 2002-03-07   See Pricing ALMIRALL, S.A. (Barcelona, ES) 2031-08-01 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Express Scripts
AstraZeneca
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.